Onxeo Expands its Pipeline with New Optimized Lead OX401 Entering Proof-of-Concept Preclinical Phase

OX401 is the second candidate utilizing Onxeo’s proprietary platform of decoy agonists, platON™ OX401 is optimized to be a next-generation PARP inhibitor, designed to act on both the DNA Damage Response and the activation of immune response In vivo proof-of-concept results alone and in combination with cancer immunotherapies are expected by early Q4 2019   Paris (France), June 20, 2019…read more →